INTRODUCTION
============

The genetic code defines the relationship between the genetic information in DNA and the amino acid sequences of proteins, with the assignment of the 64 codons to amino acids or the stop signal. These assignments have remained unchanged or 'frozen', with only rare exceptions ([@B1; @B2; @B3]), since they were presumably established in the common ancestor of all organisms. It has been argued that codon reassignment would alter the amino acid sequences of most proteins simultaneously, and thus have a destructive impact on the organism ([@B4]). This lethal effect might be avoided, if the usage of the codon to be redefined is minimized throughout the genome, prior to the codon redefinition ([@B5]), or is gradually adapted to the new assignment ([@B6]). However, each of these changes involves the accumulation of a number of mutations in the genome, which is considered to be the major constraint 'freezing' the genetic code. In the present study, we aimed to define the conditions required for the reassignment of a codon, and found that only a few mutations are needed to prepare *Escherichia coli* for the reassignment of the amber UAG triplet from a stop signal to a sense codon.

In the *E. coli* genome, the amber UAG triplet occurs at the ends of about 300 open reading frames (ORFs) (Profiling of *E. coli* Chromosome, <http://www.shigen.nig.ac.jp/ecoli/pecplus/index.jsp>). Release factor 1 (RF-1), encoded by the *prfA* gene, is the only molecule that recognizes UAG and terminates protein synthesis ([@B7]). Amber suppressor tRNAs naturally occur in *E. coli* and translate UAG to amino acids ([@B8],[@B9]). As a consequence of amber suppression, UAG is recognized ambiguously in two manners, as a sense codon and a stop signal, in the presence of competing RF-1 ([Figure 1](#F1){ref-type="fig"}). On the other hand, the complete reassignment of UAG requires the elimination of RF-1 from the cell, but the knock-out of the *prfA* gene, encoding RF-1, from the *E. coli* genome is reportedly lethal ([@B7]). Figure 1.Amber suppression and the complete reassignment of the UAG triplet from a stop to a sense codon by eliminating RF-1.

MATERIALS AND METHODS
=====================

Strains, plasmids, non-natural amino acid and mass spectrometry
---------------------------------------------------------------

The *E. coli* K12 strains, TOP10 and HST08, were purchased from Invitrogen and Takara Bio (Japan), respectively. The *hemA* and *hemK* genes, but not the intervening *prfA* gene, were cloned in the vector pAp102 ([@B10]), together with the transcriptional promoter upstream of *hemA*. The *prfA* gene, with an upstream *lacZ* promoter, was cloned in pACYC184, to create pLacPrfA. The amber suppressor tRNA^Gln^ and tRNA^Tyr^ genes, each under the control of the *E. coli tyrT* promoter, were cloned in the vector pACYC184, to create pKS3supE and pKS3supF, respectively. The plasmids pKSsupF-kan and piodoTyrRS-MJR1-kan are derivatives of the plasmid pKS3supF and TyrRS-MJR1 ([@B11]), respectively. The chloramphenicol acetyltransferase (*cat*) gene within pACYC184-kan, a kanamycin-resistant pACYC184 derivative, was engineered to contain 3 and 10 UAG triplets, to create *cat*(3Am) and *cat*(10Am), respectively. The *gst*(Am25) gene, described previously ([@B11]), was engineered to have six UAG triplets near the N-terminus, and was then placed under the control of the *tac* promoter, to create the plasmid pTacGST(6Am). 3-Iodo-[l]{.smallcaps}-tyrosine was purchased from Sigma-Aldrich, and was added to the growth media at a concentration of 0.1 g/l. Mass spectrometric analyses were commercially performed by Shimadzu Biotech (Japan).

Construction of BAC7
--------------------

The miniF replicon with the kanamycin resistance (*kan*) gene was amplified from the AcNPV bacmid (Invitrogen) by PCR with the F1 and F2 primers, as described previously ([@B12]), using PrimeStar GXL DNA polymerase (Takara Bio), to generate the vector BAC-*kan*. DNA fragments carrying seven essential genes (*coaD*, *hda*, *hemA*, *mre*C, *murF*, *lolA* and *lpxK*) were obtained by PCR with BL21(DE3) genomic DNA as the template, prepared using Dr GenTLE (Takara Bio) yeast genome extraction kit. The TAG stop triplets of these seven genes were mutagenized to TAA, by PCR amplification with mutagenic primers. The *waaA-coaD* operon, followed by the *ftsI-murE-murF* genes from the *mra* cluster, was cloned in the BAC-*kan* vector, to create the plasmid BAC*-murF-coaD*. Actually, the *ftsI-murE-murF* genes do not comprise an entire operon, since they lack a transcriptional promoter. The essential *murF* gene is probably expressed from the promoter of the upstream *waaA-coaD* operon. The *kan* gene in the BAC*-murF-coaD* plasmid was then replaced by the *hda* and *cat* genes, using the RT/ET kit, to create the BAC*-murF-coaD-had* plasmid. Meanwhile, the *mreBCD* and *ycaI-msbA-lpxK* operons were cloned together in the vector BAC-*kan*, to create the BAC*-mreC-lpxK* plasmid. The DNA fragment carrying the *mreC-lpxK* operons, prepared from this plasmid, was substituted for the *cat* gene in the BAC-*murF-coaD-hda* plasmid, to create BAC*-murF-coaD-hda-mreC-lpxK.* The *prfA* gene was removed from the *hemA-prfA-hemK* operon, to create the *hemAK* pair of genes. The downstream *rarA* was removed from the *lolA-rarA* operon, to leave a *lolA* gene with the native promoter. The *hemAK* and *lolA* genes were connected with the gentamicin resistance (*gent*) gene from the vector pFastBac1 (Invitrogen), under the control of the *kan* promoter, to create a DNA fragment consisting of the *hemA-lolA-gent* genes. The *kan* gene in the plasmid BAC*-murF-coaD-hda-mreC-lpxK* was replaced by this DNA fragment, to create the BAC7gent plasmid. The *gent* gene was replaced by the *Sh ble* Zeocin resistance (*zeo*) gene from the vector pcDNA3.1/Zeo(+) (Invitrogen), to create BAC7. BAC0 was an 'empty' BAC vector containing only the *zeo* gene. The essential genes in BAC7 were separately knocked out by the *cat* gene, to create the BAC6 plasmids.

Chromosomal engineering
-----------------------

Chromosomal engineering was performed using an RT/ET kit (Gene Bridges). To create a *prfA* conditional mutant, the DNA encoding the ribosome-binding site, the *araBAD* promoter and the *araC* gene ([@B13]) was introduced, together with the *kan* gene, into the chromosome of strain TOP10, upstream of the *hemA-prfA-hemK* operon. To knock-out *prfA*, the 50-bp N-terminal fragment and 225-bp C-terminal fragment of the *prfA*-coding sequence were linked to the 5′ and 3′ sides, respectively, of the *zeo* gene, and then introduced into the chromosome. The *supE44* (or *glnX44*) gene of HST08 was disrupted by the *cat* gene, linked to the left arm sequence (CGTACCCCAGCCAATTTATTCAAGACGCTTACCTTGTAAGTGCACCCAGT) and the right arm sequence (ATTAAAAAAGCTCGCTTCGGCGAGCTTTTTGCTTTTCTGCGTTCATTCA) at the 5′- and 3′-ends, respectively.

RESULTS
=======

Elimination of the *prfA* gene from the *E. coli* genome
--------------------------------------------------------

To determine the requirements for avoiding the lethal effect of the *prfA* disruption, we created a conditional *prfA* mutant, which repressed the expression of the essential *prfA* gene under a restrictive condition. The arabinose promoter, together with the *araC* gene encoding the regulator, was introduced into the *E. coli* chromosome upstream of the *hemA-prfA-hemK* operon. Thus, the expression of this operon was induced in the presence of [l]{.smallcaps}-arabinose and repressed by the addition of [d]{.smallcaps}-glucose to the growth media. To make only the *prfA* expression conditional, the constitutively expressed *hemA* and *hemK* genes were cloned on a plasmid, and were then introduced into the cell. The resulting cell was a conditional *prfA* mutant that did not grow in the presence of [d]{.smallcaps}-glucose, and was complemented by the introduction of another plasmid constitutively expressing the *prfA* gene ([Figure 2](#F2){ref-type="fig"}A, Lanes 1 and 2). Figure 2.Complementation experiments with the conditional *prfA* mutant. (**A**) Cell cultures, diluted from top to bottom, were spotted on growth media containing 0.4% glucose (w/v). The pACYC184 vector was introduced into the mutant (Lanes 1, 3 and 6). The *prfA* gene (Lane 2), the suppressor tRNA^Gln^ (Lanes 4 and 7) and tRNA^Tyr^ (Lanes 5 and 8) were introduced, alone (Lane 2) or together with the BAC0 'empty' plasmid (Lanes 4 and 5) or BAC7 (Lanes 7 and 8). BAC0 carried only the *zeo* gene. The iodotyrosine-incorporating plasmid was introduced, together with BAC7 (Lanes 9 and 10), in the absence (Lane 9) or presence (Lane 10) of 3-iodo-[l]{.smallcaps}-tyrosine in the medium. (**B**) Gene arrangement in BAC7. The gray arrows show the direction of the promoters. The seven essential genes are shown by white letters on the black background.

A recent report described the individual knock-outs of most of the *E. coli* genes, and revealed which genes cannot be disrupted, because of lethality (PEC, <http://www.shigen.nig.ac.jp/ecoli/pecplus/index.jsp>). Among these essential genes, we found that only seven essential ORFs (*coaD*, *hda*, *hemA*, *mre*C, *murF*, *lolA* and *lpxK*) end with UAG. We then engineered these seven ORFs to end with UAA, another stop triplet, to allow their expression even in the absence of RF-1. These seven modified ORFs were cloned, in a bacterial artificial chromosome (BAC), to create the BAC7 plasmid ([Figure 2](#F2){ref-type="fig"}B). For the genes that are part of a transcriptional unit, entire or large part of the operon was cloned in the plasmid. However, BAC7 did not support cell growth under the restrictive condition ([Figure 2](#F2){ref-type="fig"}A, Lane 6). This result suggested that the functions of additional genes, other than the seven essential genes, were also necessary for cell growth. These additionally required ORFs ending with UAG were probably prevented from being expressed, due to the absence of RF-1.

Instead of engineering more ORFs to end with UAA, we introduced the *E. coli* amber suppressor tRNA^Gln^ or tRNA^Tyr^ into the *prfA* mutant. In the absence of RF-1, UAG was to be recognized by these tRNAs, and the ORFs ending with UAG were to be extended by an in-frame UAA or UAG in the 3′ region, to produce only aberrant proteins with unnecessary peptide tails. The introduction of the suppressor tRNAs, together with BAC7, successfully complemented the *prfA* mutant, whereas the tRNA genes alone showed no complementing activity ([Figure 2](#F2){ref-type="fig"}A, Lanes 4--8). This result implied that many of the aberrant proteins with peptide tails retained their activities and were able to support cell growth, when these activities were expressed along with those of the seven essential genes.

We then examined if the *E. coli* suppressor tRNAs could be replaced with the archaeal pair of a UAG-decoding tRNA and an engineered tyrosyl-tRNA synthetase, for the complementation. This enzyme, designated as iodoTyrRS-*mj*, specifically charges the tRNA with a non-natural amino acid, 3-iodo-[l]{.smallcaps}-tyrosine, and incorporates 3-iodo-[l]{.smallcaps}-tyrosine into proteins in response to UAG in *E. coli* cells, when this amino acid is supplemented in the growth media ([@B11]). This archaeal pair exhibited complementing activity, depending on the presence of 3-iodo-[l]{.smallcaps}-tyrosine in the growth medium ([Figure 2](#F2){ref-type="fig"}A, Lanes 9 and 10). These observations suggested that the expression of a tRNA molecule able to translate UAG, in combination with the engineering of only 2% of the ORFs ending with UAG, would suffice to avoid the lethal effect of RF-1 elimination.

We applied these parameters to achieve the knock-out of *prfA* and redefinition of UAG in *E. coli* cells. The *E. coli* K-12 HST08 strain has the endogenous *supE44* gene encoding the amber suppressor tRNA^Gln^, and was transformed with BAC7gent, a gentamicin-resistant derivative of BAC7 ([Figure 3](#F3){ref-type="fig"}A). The *prfA* gene (1080 bp) was then knocked out from the chromosome by replacing a major part (51--858 bp) with the zeocin resistance (*zeo*) gene. The replacement in the resulting strain, HST08\[*supE44 prfA*::*zeo* BAC7gent\] or RFzero-q, was confirmed by sequencing the *prfA* locus, while the absence of the sequence in the genome was confirmed by PCR ([Figure 3](#F3){ref-type="fig"}B). The growth rate of RFzero-q was determined as 0.9 h^−1^, by monitoring the change in the natural logarithm of the optical density at 600 nm of the culture per hour; this rate differed little from the 1.3 h^−1^ rate of the parent HST08(BAC7gent). Figure 3.Construction of the RFzero strains. (**A**) Genetic modifications to create the RFzero strains. TF and KO mean transformation and knock-out, respectively. (**B**) PCR amplification was performed, using primers (black arrows) to amplify the entire *prfA* locus (Lanes 1 and 2) and primers (gray arrows) to amplify the *prfA* sequence inside the knocked out region (Lanes 3 and 4), with the genomic DNAs of HST08 (Lanes 1 and 3) and RFzero-q (Lanes 2 and 4) as the template. (**C**) PCR amplification of the *prfA* sequence inside the knocked out region, with the genomic DNAs of the HST08 strain (Lanes 1, 3, 5, 7, 9, 11 and 13) and the RFzero-q strain (Lanes 2, 4, 6, 8, 10, 12 and 14), each with BAC7 (Lanes 1 and 2), and BAC6 plasmids (Lanes 3--14) lacking the genes indicated above the lanes.

Finally, we determined which of the seven essential ORFs needed to be engineered to end with UAA, for the successful knock-out of the *prfA* gene. Each of the seven engineered ORFs was removed from BAC7, to create seven BAC6 plasmids. Six plasmids, except for the plasmid lacking the *hda* gene, allowed us to eliminate the *prfA* gene from the HST08 chromosome ([Figure 3](#F3){ref-type="fig"}C), indicating that at least *hda* must be engineered. We then found that engineering only *hda* was not sufficient for a successful *prfA* knock-out. The viability of the cell was impaired severely, when a few or more of the six essential ORFs were left ending with UAG. Therefore, BAC7, with all seven of the essential ORFs engineered, was used for further experiments.

Reassignment of the UAG triplet as a sense codon
------------------------------------------------

To prove the complete reassignment of UAG from a stop signal to glutamine, RFzero-q was transformed with a mutant chloramphenicol acetyltransferase (*cat*) gene, *cat*(3Am), containing three UAG triplets within the ORF ([Figure 4](#F4){ref-type="fig"}A). The transformants with the wild-type *cat* and *cat*(3Am) genes showed similar levels of chloramphenicol (Cm) resistance, up to a concentration of 400 µg/ml of Cm in the growth media ([Figure 4](#F4){ref-type="fig"}B). Furthermore, another *cat* mutant gene, with UAG in place of 10 glutamine codons, *cat*(10Am), conferred only slightly lower resistance (up to Cm 200 µg/ml) to RFzero-q than the wild-type *cat* gene ([Figure 4](#F4){ref-type="fig"}B). This finding showed that 10 UAG triplets were translated with efficiency comparable with that of the glutamine codons. The difference in the resistance level is probably caused by the fact that the UAG-reading tRNA, a mutant tRNA^Gln^, recognizes the UAG triplet with a lower efficiency than the wild-type tRNA^Gln^ reads the CAA and CAG glutamine codons. The parent HST08, also expressing the suppressor tRNA^Gln^, was transformed with *cat*(10Am), and the transformant was not resistant to Cm at ≥10 µg/ml concentrations ([Figure 4](#F4){ref-type="fig"}B). The absence of RF-1 in RFzero-q was also shown by the drastic increase in the efficiency of translating UAG as glutamine in RFzero-q, as compared with that of the nonsense suppression in competition with RF-1 in the parent HST08. Figure 4.Cm resistance of RFzero-q with the wild-type *cat* gene and the *cat*(3Am) and *cat*(10Am) mutant genes. (**A**) The amino acid sequence of the *cat*(10Am) gene is shown with X's representing the positions of UAG. The asterisks show the UAG positions in *cat*(3Am). (**B**) Each third of the upper and lower halves of each plate shows the growth of the HST08 and RFzero-q strains, respectively, transformed with the indicated *cat* genes. Cm concentrations are indicated above the plates.

To confirm the identity of the amino acid incorporated at UAG in the RFzero-q strain, six UAG triplets were introduced near the N-terminus of the glutathione *S*-transferase (GST) gene ([Figure 5](#F5){ref-type="fig"}A). This mutant gene, *gst*(6Am), produced the full-length GST in RFzero-q ([Figure 5](#F5){ref-type="fig"}A), and the product was then subjected to a mass spectrometric analysis. After trypsin digestion, the *gst*(6Am) product from RFzero-q generated a peptide with an average mass corresponding to the theoretical value (*m/z* = 1892.9) for residues 13--30 including five glutamines, and a peptide with an average mass corresponding to the theoretical value (*m/z* = 1292.7) for residues 31--41 including one glutamine ([Figure 5](#F5){ref-type="fig"}B). This result indicated that UAG was translated as glutamine in the RFzero-q strain. Figure 5.Expression of the *gst*(6Am) gene in the RFzero strains. (**A**) The N-terminal 45 residues of *gst*(6Am) are shown, where the asterisks indicate the positions of UAG triplets. The *gst*(6Am) products from RFzero-q, -y and -iy cells each with *gst*(6Am), and RFzero-iy cells without *gst*(6Am) (30-μl culture each) were subjected to SDS--PAGE and western blotting using an anti-GST antibody. Mass spectrometric analyses of the trypsin digests of the *gst*(6Am) products from RFzero-q (**B**) and RFzero-y (**C**). Theoretical (Calcd) and observed (Obsvd) values of the average masses for peptides A and B are shown.

Next, the UAG triplet was reassigned to a tyrosine codon. The *supE44* gene in the HST08 genome was disrupted, prior to the knock-out of *prfA* ([Figure 3](#F3){ref-type="fig"}A). The resulting strain was transformed with BAC7gent and a plasmid expressing the amber suppressor tRNA^Tyr^ (pKS3supF-kan). The *prfA* gene was successfully disrupted in the transformant, to create HST08\[*supE44::cat prfA::zeo* BAC7gent pKS3supF-kan\] or RFzero-y. To confirm the identity of the amino acid incorporated at UAG, the *gst*(6Am) mutant was introduced into RFzero-y. The full-length GST was produced ([Figure 5](#F5){ref-type="fig"}A), and was then subjected to a mass spectrometric analysis. The *gst*(6Am) product from RFzero-y generated a peptide with an average mass corresponding to the theoretical value (*m/z* = 2067.9) for residues 13--30 including five tyrosines, and a peptide with an average mass corresponding to the theoretical value (*m/z* = 1327.7) for residues 31--41 including one tyrosine ([Figure 5](#F5){ref-type="fig"}C). This result indicated that UAG was translated as tyrosine in RFzero-y. Together with the result obtained with RFzero-q, our findings show that UAG can be reassigned to a natural amino acid, according to the specificity of the UAG-decoding tRNA.

Reassignment of the UAG triplet to a non-natural amino acid
-----------------------------------------------------------

Finally, we examined the feasibility of genetically encoding a non-natural amino acid by codon reassignment. The RFzero-q strain was transformed with a plasmid (piodoTyrRS-MJR1-kan) expressing the iodotyrosine-incorporating tRNA--iodoTyrRS-*mj* pair ([Figure 3](#F3){ref-type="fig"}A). In this transformed strain and in the presence of 3-iodo-[l]{.smallcaps}-tyrosine, the *supE44* gene was successfully disrupted in the genome, to create HST08\[*supE44::cat prfA::zeo* BAC7gent piodoTyrRS-MJR1-kan\] or RFzero-iy. A PCR analysis of the genomic DNA of this strain confirmed that the *prfA* gene was absent, and that the *supE44* gene was replaced by the marker *cat* gene (data not shown). The growth of RFzero-iy depended on the presence of 3-iodo-[l]{.smallcaps}-tyrosine in the growth media ([Figure 6](#F6){ref-type="fig"}A), which was consistent with the observation that the iodotyrosine-incorporating tRNA--iodoTyrRS-*mj* pair complemented the *prfA* conditional mutant, depending on the presence of 3-iodo-[l]{.smallcaps}-tyrosine. Figure 6.UAG reassignment as a sense codon specifying a non-natural amino acid. (**A**) Growth of RFzero-iy cells in the presence (+IY) and absence (−IY) of 3-iodo-[l]{.smallcaps}-tyrosine (IY) supplemented in the growth media. (**B**) Mass spectrometric analysis of the trypsin digest of the *gst*(6Am) product from RFzero-iy. Theoretical (Calcd) and observed (Obsvd) values of the average masses are shown for peptides A and B.

To identify the amino acid incorporated at UAG, the *gst*(6Am) gene was introduced into RFzero-iy. The full-length GST product was produced from this mutant gene in the RFzero-iy strain ([Figure 5](#F5){ref-type="fig"}A). In a mass spectrometric analysis ([Figure 6](#F6){ref-type="fig"}B), the product generated a peptide with an average mass corresponding to the theoretical value (*m/z* = 2698.4) for residues 13--30 including five iodotyrosines (DP\*S\*S\*S\*S\*SNSGVTK, where the asterisk indicates the position of UAG triplets), and a peptide with an average mass corresponding to the theoretical value (*m/z* = 1453.6) for residues 31--41 including one iodotyrosine (NS\*SPILGYWK). This result showed that all of the six UAG triplets were translated as iodotyrosine. Thus, UAG can be completely reassigned to a novel repertoire of amino acids in the bacterial genome.

DISCUSSION
==========

The 'universal' genetic code assigns three triplets (UAG, UAA and UGA) as stop signals. Each of the eukaryal and archaeal RFs recognizes all three of these triplets ([@B14],[@B15]), while there are two types of RFs in bacterial cells: RF-1 for UAG and UAA, and RF-2 for UAA and UGA ([@B16]). The disruption of the gene encoding a RF is lethal ([@B7]), probably because the absence of the factor causes ribosome stalling at the stop triplets recognized by the factor. Although this harmful effect is reportedly suppressed, to a certain extent, by mRNA cleavage and tmRNA-mediated tagging ([@B17]), this mechanism leads to the degradation of the tagged product, and thus prevents the expression of ORFs ending with the stop triplet. When the RF-1-encoding *prfA* gene was disrupted in *E. coli*, both UAA and UGA are available as stop signals, and the UAG-ending ORFs were thus extended by an in-frame UAA or UGA triplet in the 3′ region in the presence of UAG-decoding tRNA. Although amber suppression also causes this extended translation, the UAG-ending ORFs are normally translated as well, due to the presence of RF-1. On the other hand, by the present codon reassignment, involving the knock-out of *prfA*, the UAG-ending ORFs only produced aberrant proteins with unnecessary peptide tails, in the presence of UAG-decoding tRNA.

In addition to the engineering of the seven essential ORFs, the expression of a UAG-decoding tRNA was required to avoid the lethality of RF-1 elimination. This tRNA expression not only solves the potential problem of ribosome stalling at UAG codons, but also allows the non-essential ORFs ending with UAG to be expressed, although their products have C-terminal peptide tails. A non-essential gene is defined as a gene that can be disrupted separately, and the disruption of a few or more non-essential genes at a time may impair the viability of the cell. Thus, *E. coli* growth should require the functions of many other genes, in addition to the essential genes, which account for \<10% of the genome (PEC, <http://www.shigen.nig.ac.jp/ecoli/pecplus/index.jsp>). In fact, the reduction of the *E. coli* chromosome to 70% of the original size reportedly has detrimental effects on the cell ([@B18]). In light of this knowledge, a significant proportion of the aberrant proteins, expressed from the extended ORFs, should retain their activities necessary for cell growth. We found that none of the six essential ORFs ending with UAG, except for *hda*, needed to be engineered to end with UAA, to create an RF-1-lacking strain. This finding revealed that the aberrant proteins, generated from the extension of these ORFs, retained their essential function for cell growth, suggesting that the *E. coli* proteome largely tolerates the C-terminal extension.

The second stop triplet, to terminate the translation extended by UAG readthrough, may not occur at random. In the *E. coli* genome, 42% of the UAG triplets are accompanied by a second stop triplet, UAA or UGA, occurring within 10 triplets after UAG. In contrast, a significantly smaller proportion of UAG triplets (27%) would have the second stop triplet within 10 triplets, if it were present randomly. This comparison suggests that the average aberrant protein, produced by UAG readthrough, has a shorter peptide tail than that expected from the random occurrence of the second stop triplet. This tendency of 'doubling' stop signal has also been observed in the genomes of yeasts and ciliates ([@B19],[@B20]), and might have evolved, because the unusual proteins with long C-terminal tails, produced by nonsense suppression or other events, were harmful to the organism. The double-stop-codon system, which makes the tails shorter, might have alleviated some of the detrimental effects, and as a result, facilitated the reassignment of stop codons, as naturally established in the nuclear genomes of certain organisms, including ciliates ([@B1]).

The 'ambiguous intermediate' theory has been proposed for explaining the molecular mechanism underlying the natural occurrence of codon reassignment, including sense codon reassignment ([@B6]). This theory assumes that the codon to be reassigned retains two different meanings during the period when its usage in the genome gradually adapts to the second meaning. This scenario proved valid for the UAG reassignment. Prior to the RF-1 elimination, the expression of UAG-decoding tRNA conferred double meaning on UAG, which either terminated translation or specified an amino acid. Then, the required number of UAG triplets was replaced with UAA, to make the UAG reassignment tolerable for *E. coli*. Although only a small number of UAG replacements prepared *E. coli* for the UAG reassignment, the number of genomic mutations required to achieve a sense codon reassignment may be much larger, but may also depend on the tolerance of the proteome to the event.

For the present UAG reassignment, two mutations to create a UAG-reading tRNA and to inactivate RF-1, in addition to the UAG-to-UAA synonymous changes in the seven ORFs, are required for the UAG reassignment. Since suppressor tRNAs can naturally occur in *E. coli* ([@B8],[@B9]), these nine mutations can be accumulated in the bacterial genome, with the lethal RF-1 mutation being the last. Assuming a mutation rate of 10^−9^ per base, an *E. coli* cell with all of these mutations could emerge within 270 generations starting from a single wild-type cell. Therefore, the flexibility of the genetic code is remarkably high. Nevertheless, the reassignment of UAG to a canonical amino acid has no apparent selective advantage, and would not help the cell to prevail in a mixed population. On the other hand, the reassignment to a novel amino acid could be advantageous to the organism, which would help to establish this change in the genome. A potential complexity is that more genetic changes are required, since an aminoacyl-tRNA synthetase gene must be duplicated, with the second gene being modified to create a synthetase that attaches the novel amino acid to tRNA. This is probably the case for pyrrolysine, a non-canonical amino acid, recognized by a specific synthetase and encoded by UAG in methane-generating Archaea ([@B21]). Pyrrolysine confers reproductive advantage to the organisms, by playing a catalytic role in enzymes involved in methanogenesis ([@B22]).

A novel repertoire of amino acids has been incorporated into proteins in *E. coli*, yeast, insect and mammalian cells, and has already contributed to protein science and technology ([@B23; @B24; @B25; @B26]). The previous approaches, however, relied on nonsense or frameshift suppression, with the inherent drawback of low product yields due to the competition between endogenous factors and suppressor tRNA molecules. Although an 'orthogonal' ribosome exhibiting increased suppression efficiency was recently developed ([@B27]), the competition with RF-1 still limited product yields. By eliminating the competing factor, our approach promises to drastically increase the yield of proteins containing non-natural amino acids. Furthermore, the codon reassignment allows the incorporation of these novel building blocks at multiple sites in a single protein, and will enhance the creation of proteins with novel structures and functions, as well as the preparation of proteins with naturally occurring modifications.
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